Becky McCall

South East District

Medical Journalist at Freelance

Featured in: Favicon

dailymail.co.uk Favicon

nature.com Favicon

webmd.com

thetimes.co.uk Favicon

medscape.com (+3) Favicon

medicinenet.com Favicon

thelancet.com Favicon

duluthnewstribune.com Favicon

mdedge.com Favicon

the-hospitalist.org + 6 more

Articles

Obesity by Stealth: Marketing Unhealthy Food to Teens

1 month ago | medscape.com | Becky McCall

MÁLAGA, Spain — In 2020, Portuguese football star Cristiano Ronaldo made headlines off the pitch when, during a press conference, he pointedly removed two bottles of Coca-Cola placed in front of him and held up a bottle of water instead. “Água,” he said. The clip went viral.
Tirzepatida supera semaglutida na perda ponderal

1 month ago | portugues.medscape.com | Becky McCall

MÁLAGA, Espanha — No primeiro estudo comparativo do tipo, a tirzepatida (Mounjaro para diabetes tipo 2 e Zepbound para obesidade; Eli Lilly) produziu perda ponderal significativamente maior, além de redução na circunferência da cintura, do que a semaglutida (Ozempic para diabetes tipo 2 e Wegovy para perda de peso; Novo Nordisk) em adultos com obesidade, mas sem diabetes tipo 2, ao longo de 72 semanas no estudo SURMOUNT-5.
A semaglutida pode diminuir o risco cardiovascular antes da perda ponderal

1 month ago | portugues.medscape.com | Becky McCall

Espanha — A semaglutida está associada a uma redução de 41% do risco de doença cardíaca grave em até seis meses — bem antes que os pacientes alcancem uma perda ponderal substancial ou cheguem à dose semanal total de 2,4 mg —, segundo novos dados do ensaio clínico SELECT. “A incidência acumulada de doença cardíaca grave durante os seis primeiros meses foi de 0,59”, disse a Dra. Donna, médica e professora emérita do Pennington Biomedical Research Center, nos Estados Unidos.
Quebrando o silêncio: Europa se une contra o dano relacionado ao álcool

1 month ago | portugues.medscape.com | Becky McCall

Recentemente, formou-se uma nova coalizão de organizações de saúde e especialistas na União Europeia para defender a redução de doenças, lesões e mortes relacionadas ao álcool. Anunciada no Congresso da European Association for the Study of the Liver (EASL) de 2025, a European Health Alliance on Alcohol tem como objetivo reduzir o impacto do álcool na saúde, aumentar a conscientização pública e defender a implementação de políticas eficazes para salvar vidas.
Obesity App May Enable Weight Loss With Less Semaglutide

1 month ago | medscape.com | Becky McCall

MÁLAGA, Spain — An online obesity clinic named Embla was associated with weight loss like that seen in randomized controlled trials (RCTs) of semaglutide, but with less than half of the semaglutide dose, according to new real-world data. Average weight loss reached 16.7% after 64 weeks’ use of the digital health platform, which combines tailored semaglutide dosing with intensive behavioral therapy delivered via an app.
Semaglutide May Cut Cardiovascular Risk Before Weight Loss

1 month ago | medscape.com | Becky McCall

MÁLAGA, Spain — Semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients achieve substantial weight loss or reach the full 2.4 mg weekly dose — according to new data from the SELECT trial. “The cumulative incidence of MACEs during the first 6 months showed a hazard ratio of 0.59,” said Donna Ryan, MD, professor emerita at Pennington Biomedical Research Center in Baton Rouge, Louisiana.
Waist-to-Height Ratio Predicts Heart Risk at Age 10 Years

1 month ago | medscape.com | Becky McCall

MÁLAGA, Spain — Children with a gradually increasing waist-to-height ratio trajectory (a marker of central obesity) during the first decade of life show signs of increased cardiometabolic and cardiovascular disease (CVD) risk at age 10 years, according to data from Denmark. Children who showed this gradual rise in central obesity from birth were more likely to demonstrate signs of cardiometabolic and CVD risk by age 10 years.
Tirzepatida supera a semaglutida en la pérdida de peso

1 month ago | espanol.medscape.com | Becky McCall

MÁLAGA, ESP.
Drug Slows Progression of Primary Sclerosing Cholangitis

1 month ago | medscape.com | Becky McCall

AMSTERDAM — Norucholic acid (NCA), an investigational therapy, demonstrated significant superiority over placebo in halting disease progression in patients with primary sclerosing cholangitis (PSC), meeting the primary efficacy endpoint in a phase 3 trial presented on May 10 at the European Association for the Study of the Liver (EASL) Congress 2025.
AI in Liver Care Needs Vigilance and Tailoring to Population

1 month ago | medscape.com | Becky McCall

AMSTERDAM — As artificial intelligence (AI) becomes increasingly embedded within healthcare, including liver care, it will be essential to tailor AI to the local population and ensure regular model monitoring to ensure both effective and safe outcomes for patients. Ashley Spann, MD, is a transplant hepatologist interested in developing informatics and AI to optimize outcomes in liver disease, including transplantation, at Vanderbilt University Medical Center, Nashville, Tennessee.